UK reimbursement finalized for Takeda's Entyvio
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has published final guidance approving the use of Takeda Pharmaceutical's ulcerative colitis treatment, Entyvio (vedolizumab), on the National Health Service.